Quest Diagnostics Q4 2020 Earnings Report
Key Takeaways
Quest Diagnostics reported a strong Q4 2020, with revenues up 55.8% compared to 2019. The company's performance was driven by continued high demand for COVID-19 testing. The company has increased its dividend and share repurchase authorization.
Fourth quarter revenues of $3.0 billion, up 55.8% versus 2019
Fourth quarter diluted earnings per share from continuing operations (EPS) of $4.21, up 126.9% from 2019; and adjusted diluted EPS of $4.48, up 167.7% from 2019
Full year revenues of $9.44 billion, up 22.1% from 2019
Full year diluted EPS of $10.47, up 70.8% from 2019; and adjusted diluted EPS of $11.18, up 70.4% from 2019
Quest Diagnostics
Quest Diagnostics
Forward Guidance
The company estimates its first half 2021 results as follows: LowHighNet revenues$4.85 billion$5.15 billionNet revenues increase32.9%41.1%Reported diluted EPS$5.076.07Adjusted diluted EPS$5.90$6.90Cash provided by operationsAt least $800 millionCapital expendituresApproximately $200 million